Search Orphan Drug Designations and Approvals
-
Generic Name: | 2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride |
---|---|
Date Designated: | 06/17/2019 |
Orphan Designation: | Treatment of beta-thalassemia |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Vifor Pharma, Inc. 200 Cardinal Way Redwood City, California 94063 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-